Welcome to the Stocktwits Top 25 Newsletter for Week 33 of 2022!
The Stocktwits Top 25 reports the 25 best-performing stocks in the S&P 500, Nasdaq 100, and Russell 2000 year to date (YTD) and tracks their performances over time.
Here are the Stocktwits Top 25 Lists for Week 33:
Standard and Poor's 500
ST Top 25 S&P 500
The S&P 500 Top 25 list (+1.61%) outperformed the S&P 500 index (-1.21%).
There were four major changes to the list this week.
EOG Resources (+3.72%), Pioneer Natural Resources (+3.88%), Sempra Energy (+2.22%), and APA Corp. (+4.18%) joined the list.
They replaced Lamb Weston Holdings (+0.33%), T-Mobile US (-0.06%), Quanta Services (-1.00%), and Nucor Corp. (-3.30%).
Energy stocks topped the charts again in what was a quiet week overall.
Check out how the momentum meter has performed vs. the S&P 500 index this year:
NASDAQ 100
The Large-Cap Nasdaq 100
The Nasdaq 100 Top 25 list (+0.03%) outperformed the Nasdaq 100 index (-2.38%).
There were two major changes to the list this week.
Mondelez International (+1.81%) and Regeneron Pharmaceuticals (-1.65%) joined the list.
They replaced CrowdStrike Holdings (-5.15%) and Analog Devices (-6.28%).
Overall, it was a quiet week, with some movement in the middle/end of the list. Sirius XM (-5.60%) and Synopsys (-5.82%) were two standouts on the downside.
RUSSELL 2000
The Growth-Centric Russell 2000
The Russell 2000 Top 25 list (+0.33%) outperformed the Russell 2000 index (-2.94%).
There was only one major change to the list this week.
Tidewater Inc. (+2.01%) joined the list, replacing Range Resources (-2.11%).
Rhythm Pharmaceuticals (+14.22%) and Peabody Energy (+11.32%) stood out on the upside.
Aerovate Therapeutics (-17.29%), Veru (-8.44%), and Scorpio Tankers (-6.68%) stood out on the downside.
🐶🐶🐶
ST Top 25 TOP DAWG OF THE WEEK 🐶
The Top 25 lists’ Top Dawg was Rhythm Pharmaceuticals, which rallied 14.22%.
The commercial-stage biopharmaceutical company focuses on developing and commercializing therapeutics for the treatment of rare genetic diseases of obesity. It has a market cap of $1.26 billion and has been rallying since mid-June on the back of the FDA’s approval of its lead drug, IMCIVREE. 💉
There have been other company updates since then, but we’re not smart enough to figure out what it all means. So you can check them out on the company’s website. 🤷♂️
Rhythm is the fourth biotech company in a row to achieve “Top Dawg” status, which is a testament to how hot the sector has recently been. 🔥
$RYTM is up 133.36% YTD.
See Y’all Next Week 🤙
